Abstract WMP58: Underrepresentation of Racial and Ethnic Minorities in Stroke Clinical Trials
Chigozirim Izeogu,Manish Bhojwani,Mariam Ahmed,Kelly Chang,Amol Mehta,Lamya Ibrahim,Eva Rocha,Erica Jones,Nneka L Ifejika,Nicole R Gonzales,Anjail Z Sharrief
DOI: https://doi.org/10.1161/str.55.suppl_1.wmp58
IF: 10.17
2024-02-01
Stroke
Abstract:Background: Stroke impacts Black and Hispanic individuals disproportionately compared to White individuals. Equitable inclusion in stroke research for disproportionately affected populations is critical for addressing stroke inequities. Prior literature has reported a lack of racial diversity in acute stroke trials, but data are lacking for trials conducted across the stroke care continuum. Methods: We performed a comprehensive review of completed trials registered from January 1, 1990, to April 20, 2023, in the ClinicalTrials.gov registry. Trials for stroke treatment in hyperacute, acute, and post-acute care settings were included if they were at least partially conducted in the U.S., enrolled ≥ 50 participants aged 18 and older, and published their results in a peer-reviewed journal available on PubMed or Embase. Results: 2461 trial records were retrieved, of which 69 stroke trials were included and are reported in this analysis. Overall, 34 of 69 trials (49%) included data on some racial or ethnic demographics in the primary manuscript. For trials conducted exclusively in the U.S., 20 of 30 trials (67%) reported data on race. Among international trials which also included the U.S., 14 of 39 trials (36%) reported data on race. Among trials exclusively conducted in the U.S., 74% of study participants were white. Among trials conducted exclusively in the U.S., 57% of trials funded by government reported race, whereas, 71% of trials funded by industry reported on race. Conclusion: This review shows under-reporting of race, ethnicity, and other sociodemographic data in stroke trials across the care continuum. When race and ethnicity are reported, most studies show over-presentation of White individuals, especially considering the disproportionate burden of stroke in Black and Hispanic groups. There is an urgent need to develop and implement strategies to increase diversity in stroke clinical trials to effectively understand and address inequities in stroke care and outcomes.
peripheral vascular disease,clinical neurology